STOCK TITAN
  1. Home
  2. News
  3. VKTX

Viking Therapeutics Inc - VKTX STOCK NEWS

Welcome to our dedicated news page for Viking Therapeutics (Ticker: VKTX), a resource for investors and traders seeking the latest updates and insights on Viking Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Viking Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Viking Therapeutics's position in the market.

News
Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
Rhea-AI Summary
Viking Therapeutics, a biopharmaceutical company, reported positive results from Phase 2 trials of VK2735 for obesity, showcasing up to 13.1% weight loss. The company also raised $630 million in a public offering, ending the quarter with $963 million in cash. The Phase 2b VOYAGE study evaluating VK2809 for NASH and fibrosis is progressing well, with histology results expected soon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
News
Viking Therapeutics to Report Financial Results for First Quarter 2024 on April 24, 2024
Rhea-AI Summary
Viking Therapeutics, a clinical-stage biopharmaceutical company, will report its financial results for the first quarter of 2024 on April 24, 2024. The company will host a conference call to discuss the results and general corporate updates on the same day at 4:30 p.m. Eastern Time. Investors and analysts can participate in the call by dialing the provided numbers. A telephone replay will be available until May 1, 2024, and the conference call can also be accessed live via the internet.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
News
Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735
Rhea-AI Summary
Viking Therapeutics, Inc. announces positive Phase 1 trial results for VK2735, showing up to 3.3% placebo-adjusted mean weight loss and low GI-related adverse events. Phase 2 trial for obesity planned in 2H24.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.82%
Tags
clinical trial
News
Viking Therapeutics Announces Closing of Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Rhea-AI Summary
Viking Therapeutics, Inc. announced the closing of a public offering, raising approximately $632.5 million. The offering included 7,441,650 shares of common stock at $85.00 per share, with additional shares purchased by underwriters. The proceeds will be used for the development of various programs and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.77%
Tags
offering
-
News
Viking Therapeutics Announces Pricing of $550 Million Public Offering of Common Stock
Rhea-AI Summary
Viking Therapeutics, Inc. announces the pricing of its underwritten public offering of 6,471,000 shares of common stock at $85.00 per share, aiming to raise approximately $550.0 million. The company granted underwriters an option to purchase additional shares, with all proceeds going to Viking.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.47%
Tags
offering
-
News
Viking Therapeutics Announces Proposed Public Offering of Common Stock
Rhea-AI Summary
Viking Therapeutics, Inc. announces a public offering of $350 million of common stock with an option for additional $52.5 million. The proceeds will fund the development of key programs and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.11%
Tags
offering
News
Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity
Rhea-AI Summary
Viking Therapeutics, Inc. announces positive Phase 2 trial results for VK2735, a potential treatment for metabolic disorders like obesity. Patients showed significant weight loss up to 13.1% compared to placebo, with mild and moderate adverse events. The study demonstrated VK2735's safety, efficacy, and potential for further development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
121.02%
Tags
clinical trial
-
News
Viking Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
Viking Therapeutics, Inc. announced its strong financial results for the fourth quarter and year ended December 31, 2023, and provided updates on its clinical pipeline. The company achieved significant progress with each of its four clinical programs, including the results from the Phase 1 trial of VK2735 for obesity, the VOYAGE study of VK2809 for NASH and fibrosis, and the Phase 1b study of VK0214 for X-ALD. Additionally, Viking completed 2023 with a strong cash position of $362 million, allowing the company to advance its development pipeline through important clinical milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.01%
Tags
earnings
-
News
Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2023 on February 7, 2024
Rhea-AI Summary
Viking Therapeutics, Inc. (VKTX) will release financial results for the fourth quarter and year-end 2023 on February 7, 2024. The company, focused on developing therapies for metabolic and endocrine disorders, will host a conference call to discuss financial results and corporate updates. Participants can join the call by dialing (844) 850-0543 from the U.S. or (412) 317-5199 from outside the U.S. A telephone replay will be available until February 14, 2024. The conference call can also be accessed live via the internet on Viking's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.79%
Tags
conferences earnings
News
Viking Therapeutics Presents New Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) at The Liver Meeting® 2023
Rhea-AI Summary
Viking Therapeutics, Inc. (NASDAQ: VKTX) announced new results from the Phase 2b clinical trial of VK2809, a liver-selective thyroid hormone receptor beta agonist, in patients with NASH. The study demonstrated statistically significant liver fat reductions from baseline to Week 12 among patients receiving VK2809, with up to 85% experiencing at least a 30% relative reduction in liver fat content. The results also showed comparable liver fat reductions among patients with or without type 2 diabetes, as well as those with F2 or F3 fibrosis. VK2809's potential therapeutic activity is not meaningfully impacted by the presence of type 2 diabetes or patients' stage of fibrosis, indicating its potential benefits across important disease subgroups.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.49%
Tags
clinical trial
Stock VKTX logo
Viking Therapeutics Inc

Nasdaq:VKTX

VKTX Rankings

#974 Ranked by Market Cap
#94 Ranked by Stock Gains
N/A Ranked by Dividends

VKTX Stock Data

7.56B
95.04M
5.49%
72%
8.64%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
San Diego

About VKTX

novel therapeutics for metabolic and endocrine disorders.